Unilabs, a Swiss diagnostics company, has partnered with US-based medtech C2N Diagnostics to exclusively distribute C2N’s Alzheimer’s blood tests across the EU, including Norway, Switzerland, the U.K., Peru, Saudi Arabia, and the UAE.
CRISPR has been called one of the most exciting developments in genetic engineering. It is opening up new possibilities in medicine, particularly for discovering new types of drugs for genetic diseases and new ways of repairing and replacing organs and tissue in regenerative medicine. In an interview with HBI, Philip Hargreaves, Director of Strategic Marketing & Business Development at Promega UK, the UK branch of US biotech company Promega, spoke about how CRISPR, when combined with Promega’s innovative HiBiT technology, can accelerate the drug discovery process.
European PE firm Palamon Capital has hired US investment bank Morgan Stanley to advise on a potential sale of mydentist, the UK’s largest dental chain.
London-based mid-market private equity investor Livingbridge has sold Habit Health, a leading provider of integrated rehabilitation and mental health services in New Zealand, to Australasia-based PE firm, Five V Capital.
Primary care-focused UK REIT Assura has bought the entirety of multinational hospital-focused REIT Northwest Healthcare Properties REIT’s UK portfolio. The portfolio comprises 14 hospitals with an average of 36 beds each and is worth £500 million (~€583 million).
Cymphony is a UK company that provides customer communications solutions such as telephone answering and appointment booking to private healthcare providers. In an interview with HBI, Duncan Leggat, Cymphony’s Finance Director, argued that high quality, personalised customer service is an essential part of a good healthcare service, and that, for providers focused on the premium/private-pay part of the market, the good old fashioned telephone is generally the most effective tool for achieving this.
London-based Flo Health, a menstrual cycle and ovulation tracking app, has raised over $200 million in a Series C round led by General Atlantic, a New-York based private equity firm. The funding values Flo at over $1 billion, making it the “first purely digital consumer women’s health app to achieve unicorn status”, as well as the first European femtech company to.
The British Medical Association has announced that from 1 August 2024 GPs across England can start capping the number of patients they are willing to see under an immediate work-to-rule action.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.